Skip to content
FIND A HEALTH VALLEY ACTOR

Biopôle CEO interview with FutureHealth

itw nasri futurehealth

Biopôle CEO, Nasri Nahas, talks innovation, disruptive models and technology ahead of FutureHealth Lausanne.     Mr Nahas, how is Biopôle positioning itself in the Swiss innovation market and, looking ahead over the next five years, what specific goals are you pursuing? Innovation is not only about great ideas, it is about bringing those ideas…

Read More

EPFL has developed a new AI approach to protein design

EPFL AI protein

EPFL researchers have developed a novel AI-driven model designed to predict protein sequences from backbone scaffolds, incorporating complex molecular environments. It promises significant advancements in protein engineering and applications across various fields, including medicine and biotechnology.     Designing proteins that can perform specific functions involves understanding and manipulating their sequences and structures. This task…

Read More

Release Therapeutics secures CHF 3.3 Million in seed funding

Release Therapeutics

The Campus Biotech-based BioMedTech company announced the closure of a CHF 3.3 Million Seed financing round with private investors. The financing follows the Company’s first preclinical results in animal models of metachromatic leukodystrophy (MLD).     MLD is a rare genetic disorder of the nervous system stemming from a deficiency in the lysosomal enzyme, arylsulfatase…

Read More

SamanTree Medical raises $14 Million in Series B financing round

SamanTree

SamanTree Medical, a leading medical technology company specialising in innovative solutions to improve the outcomes of surgery, announced the closing of $14 Million as part of a Series B financing round.     The new capital will be used to further develop and commercialise the Histolog® Scanner, expand its reach in Europe and the United…

Read More

Relief Therapeutics secures up to $11 Million

Relief Therapeutics

Relief Therapeutics, a biopharmaceutical company committed to delivering innovative treatment options for select specialities, unmet and rare diseases, announced the signing and closing of a definitive agreement with SWK Funding LLC (SWK).     The transaction provides the Campus Biotech-based company with non-dilutive funding to advance its pipeline, including the clinical development of its patent-protected…

Read More

New X-ray world record: looking inside a microchip with 4 nanometre precision

PSI EPFL ray X

In a collaboration with EPFL Lausanne, ETH Zurich and the University of Southern California researchers at the Paul Scherrer Institute PSI have used X-rays to look inside a microchip with higher precision than ever before.     The image resolution of 4 nanometres marks a new world record. The high-resolution three-dimensional images of the type…

Read More

AC Immune unveils novel therapeutic antibody drug conjugate (ADC)

AcImmune new drug

AC Immune, unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer® Antibody Drug Conjugate) in a presentation at the annual Alzheimer’s Association International Conference, in Philadelphia, PA.     Dr. Madiha Derouazi, Chief Scientific Officer of AC Immune, presented the characterization and in vitro efficacy of morADC for the first time. The talk,…

Read More

NOA by biped marks successful market entry in Europe and the US

Navigation, Obstacle, Artificial intelligence (NOA) is the new brand name for biped’s AI mobility vest that can guide blind and visually impaired people. Following a successful market entry in ten countries, the company has signed three distribution partnerships to fie its US launch.     Biped.ai specialises in innovative AI-powered navigation devices designed to enhance…

Read More

Oryl Photonics is awarded the EIC Transition grant with a European consortium

FASS-Oryol

Oryl Photonics achieved a significant milestone: together with its partners of the FASS – Fast and Accurate Solubility for Sustainability project, they were awarded the prestigious EIC Transition grant amounting € 2.5 Million.     The consortium is led by EU-OPENSCREEN ERIC, the European research infrastructure for early drug discovery and chemical biology with its…

Read More

UNIGE and HUG are fighting leukaemia by targeting its stem cells

By identifying mechanisms unique to leukaemia-causing cells, a French-Swiss team has discovered a new way to fight the disease.     Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva (UNIGE), University Hospital of Geneva (HUG),…

Read More